Director/PDMR Shareholding

RNS Number : 8078K
Hikma Pharmaceuticals Plc
27 June 2014
 



Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

1.      

Name of the Issuer:

 

Hikma Pharmaceuticals PLC

2.      

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006):

DTR 3.1.2 R

3.      

Name of person discharging managerial responsibilities/director:

Mohammed Ali Khaldoun S Al-Husry

4.      

State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person:

Nisreen Z. Sh. Oun Alsharifeh (wife)

Tala M. A. KH. Al-Husry (daughter)

Haya M.A. KH. Al-Husry (daughter)

Faisal Sate M. A. KH. Al Husry (son)

5.      

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest:

All persons in 3 and 4 and their shareholdings in Hikma (whether direct or indirect)

6.      

Description of shares (including class), debentures or derivatives or financial instruments relating to shares:

Ordinary Shares in Hikma

Ordinary Shares in Darhold Limited, the holding vehicle for shares in Hikma

7.      

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them:

DYKB Limited, a British Virgin Islands company which is acting as a holding company for the Al-Husry family.

8.      

State the nature of the transaction:

Encumbrance in support of a loan of the shareholdings in Hikma and Darhold belonging to DKYB Limited, on behalf of the persons noted in 3 and 4, above.

 

9.      

Number of shares, debentures or financial instruments relating to shares acquired:

None

10.    

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage):

N/A

11.    

Number of shares, debentures or financial instruments relating to shares disposed:

None

12.    

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage):

N/A

13.    

Price per share or value of transaction:

N/A

14.    

Date and place of transaction:

London, 27 June 2014

 

15.    

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage):

5,109,748 (2.61%) shares in Hikma comprising:

Directly: 1,109,748 (0.59%)

Indirectly through Darhold limited: 4,000,000 (2.02%)

16.    

Date issuer informed of transaction:

27 June 2014

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17.     

Date of grant

18.  

Period during which or date on which exercisable

19.     

Total amount paid (if any) for grant of the option

20.  

Description of shares or debentures involved (class and number)

21.     

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.  

Total number of shares or debentures over which options held following notification

23.     

Any additional information

24.  

Name of contact and telephone number for queries

 

Name of authorised official or issuer responsible for making notification

Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC

Date of notification:  27 June 2014

 

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1)           An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)           An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)           An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)           An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBUGDLGGDBGSR
UK 100

Latest directors dealings